Surgical Retinal Clinical Trial
Official title:
CD160 Expression in Retinal Vessels is Associated With Retinal Neovascular Diseases
The aims of this study were
- to analyze CD160 expression in both normal and pathological eyes from human adults
- to evaluate association between CD160 presence on endothelial cells from blood vessels
and retinal vascular disease
Anti-angiogenic agents stand first in the treatment of neovascular diseases of the retina.
Intravitreal injections of anti-Vascular Endothelial Growth Factor (VEGF) agents have emerged
over the past decade as the first line of treatment in some neovascular diseases of the
retina. Nevertheless, anti-VEGF therapies suffer some limitations, among which a short time
to recurrence (1 week to 3 months) of retinal neovascularization and an eroding biological
effect after prolonged use and.
CD160 appeared in several experimental studies as a marker of activated endothelial cells,
suggesting it could represent a promising target for novel anti-angiogenic.
;